• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

头颈部癌症患者的第三和第四种肿瘤风险。

Risk of third and fourth tumors in patients with head and neck cancer.

机构信息

Oto-rhino-laryngology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.

出版信息

Head Neck. 2010 Nov;32(11):1467-72. doi: 10.1002/hed.21348.

DOI:10.1002/hed.21348
PMID:20135631
Abstract

BACKGROUND

The objective of our study was to analyze the incidence and location of second and subsequent tumors in patients after an index head and neck carcinoma.

METHODS

A retrospective study was made by reviewing clinical data prospectively collected from 3631 patients with head and neck cancer. Incidence, location, and histology of the second, third, and fourth tumors was evaluated.

RESULTS

During the follow-up, 839 second tumors, 147 third tumors, and 35 fourth tumors were diagnosed. The annual hazard ratio was 3.8% for second tumors, 5.1% for third tumors, and 7.8% for fourth tumors. The risk of second and subsequent neoplasms remained constant throughout the follow-up. There were significant differences in the risk of appearance between the second and third tumors (p < .0001), and between the third and fourth tumors (p = .005).

CONCLUSION

Patients with a second tumor after an index head and neck carcinoma have an increased risk for developing subsequent tumors.

摘要

背景

本研究的目的在于分析头颈部癌症患者首次肿瘤确诊后的第二及后续肿瘤的发病情况和发病部位。

方法

通过对 3631 例头颈部癌症患者前瞻性收集的临床数据进行回顾性研究,评估第二、第三和第四肿瘤的发病率、发病部位和组织学特征。

结果

随访期间共诊断出 839 例第二肿瘤、147 例第三肿瘤和 35 例第四肿瘤。第二肿瘤的年危险比为 3.8%,第三肿瘤为 5.1%,第四肿瘤为 7.8%。第二和后续肿瘤的风险在整个随访期间保持不变。第二和第三肿瘤的发病风险(p <.0001)以及第三和第四肿瘤的发病风险(p =.005)存在显著差异。

结论

首次头颈部癌症确诊后发生第二肿瘤的患者,发生后续肿瘤的风险增加。

相似文献

1
Risk of third and fourth tumors in patients with head and neck cancer.头颈部癌症患者的第三和第四种肿瘤风险。
Head Neck. 2010 Nov;32(11):1467-72. doi: 10.1002/hed.21348.
2
Head and neck cancer arising after endoscopic mucosal resection for squamous cell carcinoma of the esophagus.内镜下黏膜切除术治疗食管鳞状细胞癌后发生的头颈部癌。
Endoscopy. 2003 Apr;35(4):322-6. doi: 10.1055/s-2003-38151.
3
Clinical, histological and demographic predictors for recurrence and second primary tumours of head and neck basal cell carcinoma. A 1062 patient-cohort study from a tertiary cancer referral hospital.头颈部基底细胞癌复发和第二原发肿瘤的临床、组织学和人口统计学预测因素。来自三级癌症转诊医院的 1062 例患者队列研究。
Eur J Dermatol. 2010 May-Jun;20(3):276-82. doi: 10.1684/ejd.2010.0903. Epub 2010 Apr 20.
4
Overexpression of p53 in tumor-distant epithelia of head and neck cancer patients is associated with an increased incidence of second primary carcinoma.头颈部癌症患者肿瘤远处上皮组织中p53的过表达与第二原发性癌的发病率增加有关。
Clin Cancer Res. 2001 Feb;7(2):290-6.
5
An assessment of risk factors for the development of a second primary malignancy in the head and neck.对头颈部发生第二原发性恶性肿瘤的危险因素评估。
Ear Nose Throat J. 2006 Feb;85(2):121-5.
6
Delayed regional metastases, distant metastases, and second primary malignancies in squamous cell carcinomas of the larynx and hypopharynx.喉和下咽鳞状细胞癌的区域转移延迟、远处转移及第二原发性恶性肿瘤
Laryngoscope. 2001 Jun;111(6):1079-87. doi: 10.1097/00005537-200106000-00028.
7
Tobacco smoking during radiation therapy for head-and-neck cancer is associated with unfavorable outcome.头颈部癌症放射治疗期间吸烟与不良结局相关。
Int J Radiat Oncol Biol Phys. 2011 Feb 1;79(2):414-9. doi: 10.1016/j.ijrobp.2009.10.050. Epub 2010 Apr 14.
8
[Second primary tumors in patients with carcinoma of the head and neck].[头颈部癌患者的第二原发性肿瘤]
Acta Otorrinolaringol Esp. 2000 Mar;51(2):149-53.
9
Primary and second primary cancer in 649 patients with malignancies of the maxillofacial region.649例颌面部恶性肿瘤患者的原发性和第二原发性癌症
Anticancer Res. 2007 Jul-Aug;27(4A):1805-18.
10
Second head and neck cancers and tobacco usage.继发性头颈癌与烟草使用。
Am J Otolaryngol. 2003 Jan-Feb;24(1):24-7. doi: 10.1053/ajot.2003.12.

引用本文的文献

1
The Diagnostic and Prognostic Value of F-FDG PET/MR in Hypopharyngeal Cancer.F-FDG PET/MR在下咽癌中的诊断及预后价值
Diagnostics (Basel). 2025 Aug 22;15(17):2119. doi: 10.3390/diagnostics15172119.
2
Molecular and Genetic Pathogenesis of Oral Cancer: A Basis for Customized Diagnosis and Treatment.口腔癌的分子与遗传发病机制:定制化诊断与治疗的基础
Biology (Basel). 2025 Jul 10;14(7):842. doi: 10.3390/biology14070842.
3
Indicators for secondary carcinoma in head and neck cancer patients following curative therapy: A retrospective clinical study.
根治性治疗后头颈癌患者继发性癌的指标:一项回顾性临床研究。
Mol Clin Oncol. 2020 May;12(5):403-410. doi: 10.3892/mco.2020.2004. Epub 2020 Feb 26.
4
Follow-up after treatment for head and neck cancer: United Kingdom National Multidisciplinary Guidelines.头颈癌治疗后的随访:英国国家多学科指南
J Laryngol Otol. 2016 May;130(S2):S208-S211. doi: 10.1017/S0022215116000645.
5
European Laryngological Society: ELS recommendations for the follow-up of patients treated for laryngeal cancer.欧洲喉科学会:欧洲喉科学会关于喉癌治疗患者随访的建议
Eur Arch Otorhinolaryngol. 2014 Sep;271(9):2469-79. doi: 10.1007/s00405-014-2966-x. Epub 2014 Mar 9.
6
High RAB25 expression is associated with good clinical outcome in patients with locally advanced head and neck squamous cell carcinoma.RAB25 高表达与局部晚期头颈部鳞状细胞癌患者的良好临床结局相关。
Cancer Med. 2013 Dec;2(6):950-63. doi: 10.1002/cam4.153. Epub 2013 Oct 31.
7
[Recent advances in the treatment of laryngeal and hypopharyngeal carcinoma].[喉癌和下咽癌治疗的最新进展]
HNO. 2012 Jan;60(1):6-18. doi: 10.1007/s00106-011-2422-9.